this page last modified
Leukemia: Bibliography of Relapsed ALL (Acute Lymphoblastic Leukemia) Journal Articles
The articles listed on this page in no way reflect the total number of journal articles on ALL. Some are ones which I came across or have a copy of for personal interest; some were given in online discussions; some I came across from PubMed searches. I note at each reference if I have a copy of the article and if possible give a link to the PubMed abstract. Some articles are available online as full-text web versions or pdf files.
You can do your own search on PubMed for articles on ALL (or any topic). PubMed is the National Library of Medicine's search service that provides access to over 11 million citations in MEDLINE, PreMEDLINE, and other related databases, with links to participating online journals. The PubMed link is in the navigation links on the left-side of this web page.
The articles are listed in chronological order, most recent first. Exception: Relapsed ALL articles are grouped together near the bottom of the page.
Note: some of the links expire as the hosting web site moves articles.
Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Jabbour E, et al., Cancer, 09/12/2016. Abstract.
Treatment-related adverse events associated with a modified UK ALLR3 induction chemotherapy backbone for childhood relapsed/refractory acute lymphoblastic leukemia. Weili Sun et al., Pediatric Blood & Cancer, epub 20 JUL 2016. Abstract.
Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide in Children with Advanced Acute Leukemia with a Fludarabine, Busulfan and Melphalan Based Conditioning. Jaiswal SR et al., Biol Blood Marrow Transplant, epub 2015 Nov 20. Abstract.
Intrathecal donor lymphocyte infusion for isolated leukemia relapse in the central nervous system following allogeneic stem cell transplantation: a case report and literature review. Yanagisawa R, Int J Hematol, epub 2015 Nov 19. Abstract.
Towards an understanding of the biology and targeted treatment of paediatric relapsed acute lymphoblastic leukaemia. Irving JA, Br J Haematol, epub 2015 Nov 16. Abstract.
Childhood relapsed acute lymphoblastic leukemia: Its biology and recent progress of treatment. Goto H, Pediatr Int., epub 2015 Oct 11. Abstract.
A phase I study of clofarabine with multiagent chemotherapy in childhood high risk relapse of acute lymphoblastic leukemia (VANDEVOL study of the French SFCE acute leukemia committee). Nelken B et al., Pediatr Blood Cancer. 2015 Sep 16. Abstract. "A phase I study combining escalating doses of clofarabine (25% increments from 20 to 40 mg/m2 /d) with fixed doses of mitoxantrone, etoposide, asparaginase, and dexamethasone was undertaken in children presenting with very early or second or post-transplant ALL relapse."
Profile of blinatumomab and its potential in the treatment of relapsed/refractory acute lymphoblastic leukemia. Ribera JM et al., June 2015 Volume 2015:8 Pages 1567—1574. Abstract. Full text. Promising new agent for relapsed/refractory ALL.
Successful Pregnancy and Delivery After Radiation With Ovarian Shielding for Acute Lymphocytic Leukemia Before Menarche. Ishibashi N et al., J Pediatr Hematol Oncol, epub 2015. Abstract.
Risk factors and timing of relapse after allogeneic transplantation in pediatric ALL: for whom and when should interventions be tested? Pulsipher MA et al., Bone Marrow Transplant, epub 2015 May 11. Abstract. "Patients at high risk of relapse can be defined after transplant using leukemia risk category, presence of MRD pre or post HCT, and occurrence of aGvHD. An optimal window to initiate intervention to prevent relapse occurs between day +55 and +200 after HCT."
Natural killer cell therapy in children with relapsed leukemia. Rubnitz JE et al., Pediatr Blood Cancer, epub 2015 Apr 30. Abstract. (from St. Jude)
Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2. Adamson PC et al., Pediatr Blood Cancer, epub 2015 Mar 2. Abstract.
Monitoring of Minimal Residual Disease After Allogeneic Stem-Cell Transplantation in Relapsed Childhood Acute Lymphoblastic Leukemia Allows for the Identification of Impending Relapse: Results of the ALL-BFM-SCT 2003 Trial. Bader P et al., J Clin Oncol, epub 2015 Jan 20. Abstract.
Hematopoietic stem cell transplantation following unsuccessful salvage treatment for relapsed acute lymphoblastic leukemia in children. Jiro Inagaki et al., Pediatric Blood & Cancer, epub 24 DEC 2014. Abstract.
The biology of relapsed acute lymphoblastic leukemia: opportunities for therapeutic interventions. Bhatla T et al., J Pediatr Hematol Oncol, epub 2014 Aug;36(6):413-8. Abstract. "Herein, we summarize results using a variety of genomic technologies to highlight the power of this methodology in providing insight into the biological mechanisms that impart resistant disease."
New frontiers in pediatric Allo-SCT: novel approaches for children and adolescents with ALL. Pulsipher MA et al., Bone Marrow Transplant, 2014, epub June 16. Abstract. "Recent studies have shown that relapse risk can be accurately defined using measurements of minimal residual disease (MRD) both pre- and post-HCT and by knowing whether patients get GVHD in the first 2 months after transplant. With these risk definitions in hand, investigators are now applying novel agents and immunotherapeutic methods in attempt to lower MRD before transplant and modulate the GVL effect after transplant. With powerful new immunological approaches coming on line, the transplant process itself will likely expand to include pre and/or post-HCT interventions aimed at reducing relapse."
Efficacy of prophylactic additional cranial irradiation and intrathecal chemotherapy for the prevention of CNS relapse after allogeneic hematopoietic SCT for childhood ALL. Fukano R et al., Pediatr Transplant, epub 2014 May 12. Abstract.
Feasibility of Treating Post-Transplantation Minimal Residual Disease in Children with Acute Leukemia. Shah NN et al., Biol Blood Marrow Transplant, epub 2014 Mar 27. Abstract.
Survival Improvements in Adolescents and Young Adults after Myeloablative Allogeneic Transplantation for Acute Lymphoblastic Leukemia. Wood WA et al., Biol Blood Marrow Transplant. 2014 Mar 7. Abstract.
Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab. Schlegel P et al., Haematologica, epub 2014 Apr 11. Abstract. (Germany)
Feasibility of Treating Post-Transplant Minimal Residual Disease in Children with Acute Leukemia. Shah NN et al., Biol Blood Marrow Transplant. 2014 Mar 27. Abstract.
Survival Improvements in Adolescents and Young Adults following Myeloablative Allogeneic Transplantation for Acute Lymphoblastic Leukemia. Wood WA et al., Biol Blood Marrow Transplant, epub 2014 Mar 6. Abstract.
Copy number genome alterations are associated with treatment response and outcome in relapsed childhood ETV6/RUNX1-positive acute lymphoblastic leukemia. Bokemeyer A et al., Haematologica, epub 2013 Nov 15. Abstract.
Unrelated cord blood transplantation for central nervous system relapse in high-risk childhood acute lymphoblastic leukemia. Zheng C et al., Ann Hematol. 2013 Dec;92(12):1665-73. Abstract.
A clofarabine-based bridging regimen in patients with relapsed ALL and persistent minimal residual disease (MRD). Gossai N et al., Bone Marrow Transplant, epub 2013 Dec 9. Abstract.
Interleukin-2 priming chemotherapy: A strategy to improve the remission of refractory/relapsed T cell acute lymphoblastic leukemia. Zhang C, Zhang X, Chen XH, Med Hypotheses, epub 2013 Sep 11. Abstract.
Anti-leukaemic activity of a novel haploidentical-transplantation approach employing unmanipulated bone marrow followed by CD6-depleted peripheral blood stem cells in children with refractory/relapsed acute leukaemia. Friedhelm R. Schuster et al., British Journal of Haematology, epub 6 JUL 2013. Abstract.
Use of Allogeneic Hematopoietic Stem-Cell Transplantation Based on Minimal Residual Disease Response Improves Outcomes for Children With Relapsed Acute Lymphoblastic Leukemia in the Intermediate-Risk Group. Eckert C et al., J Clin Oncol, epub 2013 Jun 17. Abstract.
Phase I/II trial of clofarabine and cytarabine in children with relapsed/refractory acute lymphoblastic leukemia (AAML0523): A report from the Children's Oncology Group. Todd M. Cooper et al., Pediatric Blood & Cancer Volume 60, Issue 7, pages 1141–1147, July 2013. Abstract.
Nelarabine for T-cell Acute Lymphoblastic Leukemia relapsing after allogeneic Hematopoietic Stem Cell Transplantation: an opportunity to improve survival. Forcade E et al., Biol Blood Marrow Transplant, epub 2013 May 3. Abstract. (Adult study; small.)
Outcomes of treatment for relapsed acute lymphoblastic leukaemia in children with Down syndrome. Meyr F et al., Br J Haematol, 2013 Apr 18. Abstract.
Clinical characteristics and outcome of isolated extramedullary relapse in acute leukemia after allogeneic stem cell transplantation: A single-center analysis. Shi JM et al., Leuk Res. 2013 Apr;37(4):372-7. Abstract.
Outcome of risk adapted therapy for relapsed/refractory acute lymphoblastic leukemia in children. Belgaumi AF et al., Leuk Lymphoma. 2013 Mar;54(3):547-54. Abstract.
Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia - Long-term results of trial ALL-REZ BFM P95/96. Eckert C et al., Eur J Cancer, epub 2012 Dec 19. Abstract.
Blockade of Lymphocyte Chemotaxis in Visceral Graft-versus-Host Disease. Ran Reshef et al., N Engl J Med. 2012 Jul 12;367(2):135-45. Abstract. "In this study, inhibition of lymphocyte trafficking was a specific and potentially effective new strategy to prevent visceral acute GVHD."
Outcomes of second allogeneic hematopoietic stem cell transplantation for patients with acute lymphoblastic leukemia. Poon LM et al., Bone Marrow Transplant, epub 2012 Oct 22. Abstract.
Phase I dose-escalation trial of clofarabine followed by escalating doses of fractionated cyclophosphamide in children with relapsed or refractory acute leukemias. Abeer Abd Elmoneim et al., Pediatric Blood & Cancer Volume 59, Issue 7, pages 1252–1258, 15 December 2012. Abstract.
Transplant conditioning regimens and outcomes after allogeneic hematopoietic cell transplantation in children and adolescents with acute lymphoblastic leukemia. Tracey J et al., Biol Blood Marrow Transplant., epub 2012 Oct 3. Abstract. "Compared to the standard regimen neither TBI in excess of 1200cGy nor the addition of etoposide improves survival after HCT for ALL."
Impact of pretransplant minimal residual disease after cord blood transplantation for childhood acute lymphoblastic leukemia in remission: an Eurocord, PDWP-EBMT analysis. Ruggeri A et al., Leukemia, epub 2012 May 4. Abstract.
RALLE Pilot: Response-guided Therapy for Marrow Relapse in Acute Lymphoblastic Leukemia in Children. Saarinen-Pihkala et al., Journal of Pediatric Hematology/Oncology: May 2012 - Volume 34 - Issue 4 - p 263–270. Abstract.
Comparison of Outcomes after HLA-matched Sibling and Unrelated Donor Transplantation for Children with High-Risk Acute Lymphoblastic Leukemia. Elizabeth L. Thiel et al., Biology of Blood and Marrow Transplantation, 04/02/2012. Abstract.
Treatment of relapsed acute lymphoblastic leukemia: Approaches used by pediatric oncologists and bone marrow transplant physicians. Michael J. Burke et al., Pediatric Blood & Cancer Volume 58, Issue 6, pages 840–845, June 2012. Abstract.
Sequential chemotherapy and myeloablative allogeneic hematopoietic stem cell transplantation for refractory acute lymphoblastic leukemia. Kotaro Arita et al., International Journal of Hematology Volume 94, Number 3, 291-295, 2011. Abstract.
Very early/early relapses of acute lymphoblastic leukemia show unexpected changes of clonal markers and high heterogeneity in response to initial and relapse treatment. C Eckert et al., Leukemia (2011) 25, 1305–1313. Abstract.
High VLA-4 expression is associated with adverse outcome and distinct gene expression changes in childhood B-cell precursor acute lymphoblastic leukemia at first relapse. Shabnam Shalapour et al., Haematologica, epub 9 August 2011. Abstract.
Autotransplantation for relapsed ALL: Going, going, gone? James Nachman, Menakshi Devidas. Pediatric Blood & Cancer Volume 57, Issue 4, pages 539–540, October 2011. Companion commentary to the article, below, by Balduzzi et al. No abstract available.
Autologous purified peripheral blood stem cell transplantation compare to chemotherapy in childhood acute lymphoblastic leukemia after low-risk relapse. Adriana Balduzzi et al., Pediatric Blood & Cancer, first published online: 16 MAY 2011. Abstract.
Minimal residual disease detected prior to hematopoeitic cell transplantation. Jennifer H. Foster et al., Pediatric Blood & Cancer, first published online: 2 MAR 2011. Abstract. "Among 116 pediatric patients with ALL who were in morphological remission at time of transplant, we found that those patients who had detectable residual disease by FCM prior to HCT experienced significantly inferior outcome."
Outcome after first relapse in children with acute lymphoblastic leukemia: A report based on the Dutch Childhood Oncology Group (DCOG) relapse all 98 protocol. H. van den Berg et al., Pediatric Blood & Cancer, first published online: 18 FEB 2011. Abstract.
Post-relapse survival in childhood acute lymphoblastic leukemia is independent of initial treatment intensity: a report from the Children's Oncology Group. David R. Freyer et al., Blood First Edition Paper, prepublished online December 30, 2010. Abstract. "As expected, PRS [post-relapse survival] was worse for early vs. late relapse, marrow vs. extramedullary site, adolescent vs. younger age and T- vs. B-lineage. However, no difference in 3-year PRS was detected for having received augmented vs. standard intensity post-induction intensification."
Phase 1 trial and pharmacokinetic study of the farnesyl transferase inhibitor tipifarnib in children and adolescents with refractory leukemias: A report from the Children's Oncology Group. Brigitte C. Widemann et al., Pediatric Blood & Cancer, Volume 56, Issue 2, pp. 226-233. Abstract.
Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): An open-label randomised trial. Catriona Parker et al., The Lancet, Volume 376, Issue 9757, pp. 2009 - 2017, 11 December 2010. Abstract. They compared mitoxantrone with idarubicin and found a 20% greater survival rate with the mitoxantrone. There are side effects (but not worse than other drugs) and some reservations of other researchers (small study size), but in general it does sound promising! They stopped the study early and put all patients on the mitoxantrone. The trial was in New Zealand/UK/Ireland/Australia and mitroxantrone is not currently in US pediatric ALL trials, except in one infant ALL trial and one ALL trial of 15-63 year olds.
Outcome of children and adolescents with relapsed acute lymphoblastic leukaemia and non-response to salvage protocol therapy: A retrospective analysis of the ALL-REZ BFM Study Group. Arend von Stackelberg et al., European Journal of Cancer, published online 22 October 2010. Abstract.
Liposomal cytarabine is effective and tolerable in the treatment of CNS relapse of acute lymphoblastic leukemia (ALL) and very aggressive lymphoma. Nicola Goekbuget et al., Haematologica, published online 15 October 2010. Abstract. Phase II trial.
Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia. Anjali S. Advani et al., British Journal of Haematology, Article first published online: 29 SEP 2010. Abstract. An adult trial, "This regimen lacked sufficient activity to warrant further testing."
Allogeneic hematopoietic cell transplantation outcomes for children with B-precursor acute lymphoblastic leukemia and early or late BM relapse. J C Beck et al., Bone Marrow Transplantation advance online publication 20 September 2010. Abstract. "Five year OS/DFS were similar for patients with an early or late marrow relapse, but there was inferior DFS among late-relapse patients transplanted in CR3 compared with CR2 (30% vs 75%, P=0.04). These results suggest that allo-HCT should be pursued in children after a first marrow relapse, rather than waiting for subsequent recurrence."
Preemptive alloimmune intervention in high-risk pediatric acute lymphoblastic leukemia patients guided by minimal residual disease level before stem cell transplantation. A C Lankester et al., Leukemia advance online publication 10 June 2010, Abstract. "We conclude that in children with high-risk ALL, immunotherapy-based regimens after SCT are feasible and may need to be further intensified to achieve total eradication of residual leukemic cells."
Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma. Leah A. Commander et al., British Journal of Haematology British Journal of Haematology, Published Online: 26 May 2010. Abstract. "Our experience supports the safety of giving AraG as salvage therapy in synchrony with etoposide and cyclophosphamide, although neurological toxicity must be closely monitored."
Relapsed childhood high hyperdiploid acute lymphoblastic leukemia: presence of preleukemic ancestral clones and the secondary nature of microdeletions and RTK-RAS mutations. J Davidsson et al., Leukemia, May 2010 Volume 24 Number 5, pp 909 - 1103, pp. 924-931. Abstract.
Autologous purified peripheral blood SCT in childhood low-risk relapsed ALL. A Balduzzi et al., Bone Marrow Transplantation advance online publication 26 April 2010. Abstract. Italian study of 30 children with isolated extra-medullary or late medullary relapse. 5 year EFS about 70-85%.
Long-Term Outcome in Children With Relapsed Acute Lymphoblastic Leukemia After Time-Point and Site-of-Relapse Stratification and Intensified Short-Course Multidrug Chemotherapy: Results of Trial ALL-REZ BFM 90. Gesche Tallen et al., Journal of Clinical Oncology, Vol 28, No 14 (May 10), 2010: pp. 2339-2347. Abstract. "More than one third of patients in this large, population-based trial were cured. Neither R3 nor adaptation of chemotherapy intensity was capable of improving pEFS or of overcoming prognostic factors. In high-risk patients, remission induction regimens must be improved, and allogeneic SCT should be recommended in patients achieving second complete remission." Note: this is chemo/radiation treatment, not transplant.
Activity and safety of combination chemotherapy with methotrexate, ifosfamide, l-asparaginase and dexamethasone (MILD) for refractory lymphoid malignancies: A pilot study. Yutaka Tsukune et al., European Journal of Haematology, Volume 84 Issue 4, pp. 310-315. Abstract.
A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia. N Hijiya et al., Leukemia advance online publication 10 September 2009. Abstract. Phase I trial of this drug combination is promising.
Temozolomide and cisplatin in relapsed/refractory acute leukemia. Karen Seiter et al., Journal of Hematology & Oncology 2009, 2:21. Abstract.
Prognostic Value of Minimal Residual Disease Quantification Before Allogeneic Stem-Cell Transplantation in Relapsed Childhood Acute Lymphoblastic Leukemia: The ALL-REZ BFM Study Group. Peter Bader et al., Journal of Clinical Oncology, Vol 27, No 3 (January 20), 2009: pp. 377-384. Abstract.
Minimal residual disease is an important predictive factor of outcome in children with relapsed /'high-risk/' acute lymphoblastic leukemia. M Paganin et al. Leukemia (2008) 22, 21932200. Abstract.
Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study. K Nguyen et al. Leukemia (2008) 22, 21422150. Abstract.
Efficacy and safety of intrathecal liposomal cytarabine for the treatment of meningeal relapse in acute lymphoblastic leukemia: Experience of two pediatric institutions. Rosanna Parasole et al. Leukemia and Lymphoma, Volume 49, Issue 8 August 2008 , pages 1553 - 1559. Abstract.
Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study. K Nguyen et al. Leukemia advance online publication 25 September 2008. Abstract.
First isolated extramedullary relapse in children with B-cell precursor acute lymphoblastic leukaemia: Results of the Cooprall-97 study. Carine Domenech et al. European Journal of Cancer pub. online 9/08. Abstract.
Efficacy and safety of intrathecal liposomal cytarabine for the treatment of meningeal relapse in acute lymphoblastic leukemia: Experience of two pediatric institutions. Rosanna Parasole et al. Leukemia and Lymphoma, Volume 49, Issue 8 August 2008 , pages 1553 - 1559. (Italy) Abstract. "Our results suggest that DepoCyte is a valid option for children with ALL experiencing meningeal relapse; it deserves further investigation in intensive treatment regimens, taking into due consideration potential neurotoxicity."
Reinduction Platform for Children With First Marrow Relapse in Acute Lymphoblastic Lymphoma. Elizabeth A. Raetz et al. Journal of Clinical Oncology, Vol 26, No 24 (August 20), 2008: pp. 3971-3978. Abstract. (COG) AALL01P2 study. "Conclusion: The AALL01P2 regimen is a tolerable and active reinduction platform, suitable for testing in combination with novel agents in B-precursor ALL. Alternative strategies are needed for T-ALL. Serial MRD measurements were feasible and prognostic of outcome."
Chemoimmunotherapy Reinduction With Epratuzumab in Children With Acute Lymphoblastic Leukemia in Marrow Relapse: A Children's Oncology Group Pilot Study. Elizabeth A. Raetz et al. Journal of Clinical Oncology, Vol 26, No 22 (August 1), 2008: pp. 3756-3762. Abstract. Epratuzumab is a humanized monoclonal antibody against CD22.
Allogeneic hemopoietic stem cell transplantation for childhood acute lymphoblastic leukemia in second complete remissionSimilar Outcomes After Matched Related and Unrelated Donor Transplant: A Study of the Spanish Working Party for Blood and Marrow Transplantation in Children (Getmon). A. Munoz et al. Pediatric Hematology and Oncology, Volume 25, Issue 4 May 2008, p. 245-259. Abstract.
Allogeneic Hematopoietic Cell Transplantation in Children with Relapsed Acute Lymphoblastic Leukemia Isolated to the Central Nervous System. Paul D. Harker-Murray et al. Biology of Blood and Marrow Transplantation, Volume 14, Issue 6, June 2008, Pages 685-692. Abstract.
High-dose compared with intermediate-dose methotrexate in children with a first relapse of acute lymphoblastic leukemia. Arend von Stackelberg et al., Blood, 1 March 2008, Vol. 111, No. 5, pp. 2573-2580. Abstract. Results of a study by the ALL-REZ BFM Study Group.
A Phase 1 and pharmacokinetic clinical trial of paclitaxel for the treatment of refractory leukemia in children: A Children's Oncology Group study. Terzah M. Horton et al. Pediatric Blood & Cancer, Volume 50, Issue 4, p. 788-792, 2008. Abstract.
Outcomes after HLA-matched sibling transplantation or chemotherapy in children with acute lymphoblastic leukemia in a second remission after an isolated central nervous system relapse: a collaborative study of the Children's Oncology Group and the Center for International Blood and Marrow Transplant Research. M Eapen et al. Leukemia, (2008) 22, 281286. Abstract.
Outcome of haematopoietic stem cell transplantation for paediatric acute lymphoblastic leukaemia in third complete remission: a vital role for graft-versus-host-disease/ graft-versus-leukaemia effect in survival. Gassas et al. British Journal of Haematology, Volume 140, Number 1, January 2008 , pp. 86-89(4). Abstract.
Phase 2 study of docetaxel in the treatment of childhood refractory acute leukemias: A Children's Oncology Group report. Janet L. Frankli, Pediatric Blood & Cancer, Volume 50, Issue 3, 2008, pp. 533-536. Abstract.
Outcome After Relapse Among Children With Standard-Risk Acute Lymphoblastic Leukemia: Children's Oncology Group Study CCG-1952. Suman Malempati, Paul S. Gaynon, Harland Sather, Mei K. La, Linda C. Stork. Journal of Clinical Oncology, Vol 25, No 36 (December 20), 2007: pp. 5800-5807. Abstract.
A phase I study of clofarabine in combination with cyclophosphamide and etoposide: A new regimen in pediatric patients with refractory or relapsed acute leukemia. N. Hijiya, J. Franklin, M. Rytting, T. Cooper, R. Chu, E. Barry, C. McCarthy, R. Abichandani, and W. Carroll. ASCO Meeting Abstracts. 2007; 25(18_suppl): p. 9529. Abstract.
Chemoimmunotherapy reinduction with epratuzumab in children with ALL with marrow relapse: A Children's Oncology Group (COG) pilot study (ADVL04P2) E. A. Raetz, M. S. Cairo, M. J. Borowitz, S. M. Blaney, M. D. Krailo, T. A. Leil, D. M. Goldenberg, W. A. Wegener, W. L. Carroll, and P. C. Adamson ASCO Meeting Abstracts. 2007; 25(18_suppl): p. 9513. Abstract.
High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study. Tedeschi, A., et al. Cancer Chemotherapy and Pharmacology, Volume 59, Number 6, June 2007, pp. 771-779(9). Abstract.
Identification of novel molecular prognostic markers for paediatric t-cell acute lymphoblastic leukaemia. Gottardo, N.G., et al. Br J Haematol. 2007 May;137(4):319-28. PubMed Abstract.
Long term disease-free survival in acute leukemia patients recovering with increased [gamma][delta] T cells after partially mismatched related donor bone marrow transplantation. Godder, K.T., et al. Bone Marrow Transplant. 2007 Apr 23. PubMed Abstract.
Patients with adenosine deaminase deficiency surviving after hematopoietic stem cell transplantation are at high risk of CNS complications. Manfred Hönig et. al., Blood, 15 April 2007, Vol. 109, No. 8, pp. 3595-3602. Abstract.
A Phase 1 Study of the Proteasome Inhibitor Bortezomib in Pediatric Patients with Refractory Leukemia: a Children's Oncology Group Study. Terzah M. Horton, et al. Clin Cancer Res. 2007 Mar 1;13(5):1516-22. PubMed abstract.
Bone Marrow Transplantation Versus Prolonged Intensive Chemotherapy for Children With Acute Lymphoblastic Leukemia and an Initial Bone Marrow Relapse Within 12 Months of the Completion of Primary Therapy: Children's Oncology Group Study CCG-1941. Paul S. Gaynon, Richard E. Harris, et al. Abstract. "BMT is not a complete answer to the challenge of ALL and early marrow relapse."
Isolated CNS Relapse of Acute Lymphoblastic Leukemia Treated With Intensive Systemic Chemotherapy and Delayed CNS Radiation: A Pediatric Oncology Group Study. Julio C. Barredo, Meenakshi Devidas, et al. Journal of Clinical Oncology, Vol 24, No 19 (July 1), 2006: pp. 3142-3149. Abstract. "Twelve months of intensive systemic chemotherapy with reduced dose cranial radiation (18 Gy) is highly effective for children with isolated CNS relapse and CR1 of 18 months or more. Novel strategies are needed for patients with CR1 of less than 18 months." Also: Outcome of the Rotterdam-84 CNS-ALL chemotherapy protocol without radiotherapy for isolated central nervous system relapsed acute lymphoblastic leukaemia. Auke Beishuizen, Femke K Aarsen, Maarten Lequin, Jeanette EWM van Dongen, Herbert Hooijkaas and Karel Hählen. Presented at the BFM Leukemia Conference 2006.
Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a Children's Oncology Group study. Deepa Bhojwani, Huining Kang, et al. Blood, 15 July 2006, Vol. 108, No. 2, pp. 711-717. Abstract. "To gain insight into the mechanisms of relapse, we analyzed gene-expression profiles in 35 matched diagnosis/relapse pairs as well as 60 uniformly treated children at relapse using the Affymetrix platform. . . These results suggest that early-relapse results from the emergence of a related clone, characterized by the up-regulation of genes mediating cell proliferation. In contrast, late relapse appears to be mediated by diverse pathways."
Bone Marrow Transplantation Versus Prolonged Intensive Chemotherapy for Children With Acute Lymphoblastic Leukemia and an Initial Bone Marrow Relapse Within 12 Months of the Completion of Primary Therapy: Children's Oncology Group Study CCG-1941. J Clin Oncol. 2006 May 22. PubMed Abstract.
Outcomes after HLA-matched sibling transplantation or chemotherapy in children with B-precursor acute lymphoblastic leukemia in a second remission: a collaborative study of the Children's Oncology Group and the Center for International Blood and Marrow Transplant Research. Mary Eapen, Elizabeth Raetz, Mei-Jie Zhang, Catherine Muehlenbein, Meenakshi Devidas, Thomas Abshire, Amy Billett, Alan Homans, Bruce Camitta, William L. Carroll, Stella M. Davies. Blood, 15 June 2006, Vol. 107, No. 12, pp. 4961-4967. Abstract.
A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in first or second complete remission. Biol Blood Marrow Transplant. 2006 Apr;12(4):438-53. Marks DI et al. PubMed abstract.
Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia. Sramkova L, Muzikova K, Fronkova E, Krejci O, Sedlacek P, Formankova R, Mejstrikova E, Stary J, Trka J. Pediatr Blood Cancer. 2006 Mar 6. Abstract.
Outcomes after HLA-matched sibling transplants or chemotherapy in children with B-precursor acute lymphoblastic leukemia in a second remission: a collaborative study of the Children's Oncology Group and the Center for International Blood and Marrow Transplant Research. Mary Eapen, Elizabeth Raetz, Mei-Jie Zhang, Catherine Muehlenbein, Meenakshi Devidas, Thomas Abshire, Amy Billett, Alan Homans, Bruce Camitta, William L Carroll, and Stella M Davies. Blood First Edition Paper, prepublished online February 21, 2006. Abstract.
Childhood acute lymphoblastic leukaemia and relapse. Paul S. Gaynon, British Journal of Haematology, 131, 579587, 2005. Review article.
Allogeneic stem cell transplantation in children with acute lymphoblastic leukemia after isolated central nervous system relapse: our experiences and review of the literature. T Yoshihara, A Morimoto, H Kuroda, T Imamura, H Ishida, K Tsunamoto1, M Naya, S Hibi, S Todo and S Imashuku. Bone Marrow Transplantation (2006) 37, 2531. Abstract.
Treatment of acute lymphocytic leukemia using zinc adjuvant with chemotherapy and radiation--a case history and hypothesis. Eby GA. Med Hypotheses. 2005;64(6):1124-6. PubMed Abstract.
Outcome after first relapse in childhood acute lymphoblastic leukaemia - lessons from the United Kingdom R2 trial. Roy A, Cargill A, Love S, Moorman AV, Stoneham S, Lim A, Darbyshire PJ, Lancaster D, Hann I, Eden T, Saha V. Br J Haematol. 2005 Jul;130(1):67-75. PubMed Abstract.
Childhood acute lymphoblastic leukaemia and relapse. Review. British Journal of Haematology. Volume 0 Issue 0 - October 2005. doi:10.1111/j.1365-2141.2005.05773. Paul S. Gaynon. Abstract.
Isolated testicular relapse in acute lymphoblastic leukemia - Effective treatment with the modified CCG-112 protocol. Shama G, Bhagwat R, Pai SK, Kurkure PA, Nair CN, Parikh PM, Mukaden MA, Banavali SD. Indian J Cancer. 2005 Apr-Jun;42(2):65-9. PubMed Abstract.
Survival after relapse in childhood acute lymphoblastic leukemia: impact of site and time to first relapse--the Children's Cancer Group Experience. Gaynon PS, Qu RP, Chappell RJ, Willoughby ML, Tubergen DG, Steinherz PG, Trigg ME. Cancer 1998 Apr 1;82(7):1387-95. PubMed abstract. This article gives relapse efs numbers according to relapse site(s).
The UK experience in treating relapsed childhood acute lymphoblastic leukaemia: a report on the medical research council UKALLR1 study. Lawson SE, Harrison G, Richards S, Oakhill A, Stevens R, Eden OB, Darbyshire PJ. Br J Haematol 2000 Mar;108(3):531-43. PubMed abstract.
Comparison of allogeneic transplant versus chemotherapy for relapsed childhood acute lymphoblastic leukaemia in the MRC UKALL R1 trial. MRC Childhood Leukaemia Working Party. Harrison G, Richards S, Lawson S, Darbyshire P, Pinkerton R, Stevens R, Oakhill A, Eden OB. Ann Oncol 2000 Aug;11(8):999-1006. PubMed abstract.
Survival and endocrine outcome after testicular relapse in acute lymphoblastic leukaemia. Grundy RG, Leiper AD, Stanhope R, Chessells JM. Arch Dis Child 1997 Mar;76(3):190-6. PubMed abstract. Full Text.
Relapsed lymphoblastic leukaemia in children: a continuing challenge. Chessells JM. Br J Haematol 1998 Jul;102(2):423-38. PubMed abstract not available. I have a hard copy of this article.
ASCO online, links to abstracts on pediatric lymphoma and leukemia.
American Society of Hematology. Articles on ALL that you can download as pdf's. This is an changing site, therefore I'm not listing what they have, you must go there to see what is currently listed. Here are a couple titles to whet your appetite.
- Mechanisms of Leukemogenesis: Chromosomal Translocations
- Adolescents and Young Adults with Acute Lymphoblastic Leukemia--A Pediatric Oncology Perspective
- Ham-Wasserman Lecture: Cord Blood Hematopoietic Stem Cells: Biology and Transplantation
ASCO - Treatment of Patients with Relapsed Leukemia, slide shows.
Also of note, from the SEER project (The National Cancer Institute - NCI - monograph, Cancer Incidence and Survival among Children and Adolescents):
- leukemia.pdf (click on leukemia under Monograph Chapters)
International Society of Haemotology, Education program:
- 1999, has an excellent article on the Treatment of ALL, comparing the different protocols from about 184-1995. PDF files, full text.
- 2002, has abstracts rather than full text.
UC Berkeley Web Site: Go to the main UC Berkeley web site and Type in the word "leukemia" where it says Search Berkeley web site to pull up about 10 pages of articles. (2003 note.)
These pages are intended for informational purposes only and are not intended to render medical advice. The information provided on Ped Onc Resource Center should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you suspect your child has a health problem, you should consult your health care provider.